altered peptide ligands peptide - alumiermd-everactive-c-e-peptide peptide Altered Peptide Ligands: Modulating Immune Responses Through Subtle Molecular Changes

xa5-peptide Altered peptide ligands (APLs) represent a fascinating area of immunological research, focusing on how minor modifications to naturally occurring peptides can profoundly influence immune responses.Altered Peptide Ligand Antagonism: From Immune Evasion to ... These peptide variants derived from the original antigenic peptide are created by introducing specific amino acid modifications, often through substitutions at particular residues. This seemingly small alteration can lead to significant functional differences, allowing APLs to act as modulators of immune responses, either by downregulating or upregulating them.作者：LA Smyth·1998·被引用次数：80—In this study we show that this antagonistpeptidecan induce positive selection of CD8+thymocytes more efficiently than the agonist or the weak agonist ... The study of altered peptide ligands has opened new avenues for therapeutic interventions in various diseases, from autoimmune disorders to infectious diseases and cancer.

The concept of altered peptide ligands emerged from the understanding that T cell receptor recognition is highly sensitive to the precise structure of the peptide presented by major histocompatibility complex (MHC) molecules.作者：P Conlon·2002·被引用次数：11—Overall, the results of the two trials with APLs in MS show that there was “no substantial improvement or worsening in the whole cohort of 8 MS patients treated ... Subtle molecular changes in peptide antigens, such as a single amino acid substitution, can produce altered peptide ligands that induce different T cell responses compared to the native peptide. This phenomenon was first described in seminal reports in the early 1990s, highlighting how these modified ligands could impact T cell signaling and subsequent immune cell activity.作者：J Sloan-Lancaster·1995·被引用次数：92—Investigations of T-cell responses toaltered peptide ligandshave provided functional evidence that a T-cell receptor can interpret subtle structural changes ... For instance, APLs derived from myelin basic protein peptide (87–99) have been investigated for their potential in treating multiple sclerosis. Research has shown that these altered peptide ligands can bind to the same MHC and T-cell receptor as the autoantigenic peptide but may fail to fully activate the T cell, potentially leading to immune tolerance or modulation.

One of the key insights into APLs is their ability to induce a qualitatively different pattern of signal transduction events compared to the native ligand. This means that even at equivalent concentrations, an altered peptide ligand can trigger a distinct cellular cascade. This has been observed in studies where APLs can induce delayed T cell receptor signaling in CD8-T cells, suggesting a nuanced control over immune cell activation作者：N Zoupanou·2024—Altered peptide ligands refer toamino acid modificationsof either those used to bind into pockets within the major histocompatibility complex (MHC) or of .... Furthermore, APLs have been shown to narrow the repertoire of cellular responses, implying a more targeted or differentiated immune outcome.作者：P Conlon·2002·被引用次数：11—Overall, the results of the two trials with APLs in MS show that there was “no substantial improvement or worsening in the whole cohort of 8 MS patients treated ... This is crucial because epitopes modified based on amino acid substitutions can lead to either agonist, partial agonist, or even antagonist effects on T cells. For example, an altered peptide ligand of type II collagen, referred to as A9, has been developed to differentially regulate TCR signaling in murine T cells, demonstrating the precision achievable with these modified peptides.Thealtered peptide ligandwould bind to the same MHC and T-cell receptor as the autoantigenic peptide from which it derives, but it would fail to activate the ...

The therapeutic potential of altered peptide ligands is vast.Identification and Targeting of Mutant Peptide Neoantigens ... They have been employed as immunotherapeutics in conditions like multiple sclerosis, where they aim to re-educate the immune system to tolerate self-antigens. Early clinical trials with APLs in multiple sclerosis showed mixed results, with some patients experiencing exacerbations, underscoring the complexity of their application and the need for careful patient selection and monitoring. However, the underlying principle of using altered peptide ligands for immune intervention remains promising. They can act as competitive inhibitors of autoimmune responses or be engineered for vaccine design to elicit specific types of immunity, such as shifting responses from T helper 1 (Th1) to T helper 2 (Th2).

Beyond autoimmune diseases, APLs hold promise in cancer therapy by targeting tumor-specific antigens or by modulating anti-tumor immunityStudying Peptide-Metal Ion Complex Structures by Solution .... The identification and targeting of mutant peptide neoantigens, which are essentially altered amino acid sequences, allow the immune system to recognize and eliminate mutated cells.作者：JE Park·2012·被引用次数：10—We have developed analtered peptide ligand of type II collagen, referred to as A9, which differentially regulates TCR signaling in murine T cells leading to ... This concept is closely related to the broader application of altered peptide ligands in vaccine development, where modifications to known epitopes can enhance immunogenicity or alter the type of immune response generatedSpecific Immunotherapy of Multiple Sclerosis by Altered ....

The study of APLs also extends to understanding fundamental immunological processes. For instance, the recognition of altered peptide ligands by T cells has provided functional evidence that a T-cell receptor can interpret subtle structural changes in a peptide, leading to distinct downstream effects. This sensitivity is critical, as even conservative amino acid changes can lead to significant alterations in the overall peptide conformation, influencing its interaction with MHC molecules and T cell receptors. The field also encompasses related concepts, such as the role of Arginylglycylaspartic acid (RGD) motifs in cell adhesion, though this is a distinct area from the immunomodulatory function of APLsThealtered peptide ligandwould bind to the same MHC and T-cell receptor as the autoantigenic peptide from which it derives, but it would fail to activate the ....

In summary, altered peptide ligands represent a sophisticated approach to manipulating immune responses. By leveraging subtle amino acid modifications within peptides, researchers can generate molecules that modulate T cell signaling and influence the overall immune outcome.On Peptides and Altered Peptide Ligands - PubMed Central This has led to their exploration as therapeutic agents for a range of conditions, highlighting the power of precisely engineered ligands in the complex landscape of immunology. The ongoing research into APLs continues to deepen our understanding of immune recognition and pave the way for innovative therapeutic strategies.